Showing 7061-7070 of 7671 results for "".
- Galderma to Enter Nutraceutical Markethttps://practicaldermatology.com/news/galderma-to-enter-nutraceutical-market/2458954/Galderma entred into the nutraceutical market through the acquisition of certain assets of Inneov Group. Relevant Inneov products are marketed under the brand names Nutri-Care D, Duocap, Densilogy, Densilogy Men, Fermete, Fermete Aox, Firmness, Pre-Hyaluron 465, Solar and Sun Sensitivity.
- AcneCareMD Website Launcheshttps://practicaldermatology.com/news/acnecaremd-website-launches/2458957/Jamie Altman, MD, owner and president of Aesthetic Dermatology Associates, PC, in Media and Paoli, PA, launched AcneCareMD.com, a secure telemedicine website to provide acne care to patients across Pennsylvania via
- ASDS Honors Legacy of Dr. Fredric Brandthttps://practicaldermatology.com/news/asds-honors-legacy-of-dr-fredric-brandt/2458958/The American Society for Dermatologic Surgery is paying tribute to the late cosmetic dermatologist Fredric S. Brandt, MD by setting up two memorial funds in his honor. Dr. Brandt, an ASDS member since 1982, died earlier this month at age 65 at his Florida home. The ASDS said the funds are
- RXi Pharmaceuticals Receives FDA Orphan Drug Designation for Samcyprone for Melanomahttps://practicaldermatology.com/news/rxi-pharmaceuticals-receives-fda-orphan-drug-designation-for-samcyprone-for-melanoma/2458964/The FDA granted RXi Pharmaceuticals Corporation Orphan Drug Designation of its second clinical candidate, Samcyprone™, for the treatment of malignant melanoma Stage IIb to IV. A number of patients with Stage IIb to IV malignant melanoma develop cutaneous metastases. Samcyprone™ is bei
- Provectus Opens Phase 3 Trial Enrollment for Investigational Melanoma Agenthttps://practicaldermatology.com/news/provectus-opens-phase-3-trial-enrollment-for-investigational-melanoma-agent/2458965/Provectus Biopharmaceuticals, Inc. has opened enrollment of patients for its phase 3 international FDA comparative clinical trial of PV-10 for melanoma. The study is an international multicenter, open-label, randomized controlled trial of single-agent intralesional PV-10 versus systemic chemother
- Senate Passes Bill to Repeal SGRhttps://practicaldermatology.com/news/senate-passes-bill-to-repeal-sgr/2458967/This week saw the end of the sustainable growth rate (SGR), with the US Senate passing the Medicare Access and CHIP Reauthorization Act (H.R.2) in a 92-8 vote and President Obama signing it into law. The bill, which the Hous
- Foamix Pharmaceuticals Announces Upsizing and Pricing of Its Public Offeringhttps://practicaldermatology.com/news/foamix-pharmaceuticals-announces-upsizing-and-pricing-of-its-public-offering/2458968/Foamix Pharmaceuticals Ltd. (Nasdaq:FOMX), a specialty pharmaceutical company focused on developing topical foams to address unmet needs in dermatology, today announced the pricing of an upsized public offering of 6,451,612 ordinary shares at a price to the public of $9.30 per share. In addition,
- Association of Dermatology Administrators and Managers Names Alice Hyman “Practice Manager of the Year”https://practicaldermatology.com/news/association-of-dermatology-administrators-and-managers-names-alice-hyman-practice-manager-of-the-year/2458966/The Association of Dermatology Administrators and Managers (ADAM) named Alice Hyman of Advanced DermCare in Danbury, CT, the recipient of this year’s Practice Manager of the Year award. She was recognized at the 23rd annual ADAM meeting in San Francisco. Ms. Hyma
- Nerium International Announces Exclusive Usage of Anti-Aging Ingredient SIG-1273https://practicaldermatology.com/news/nerium-international-announces-exclusive-usage-of-anti-aging-ingredient-sig-1273/2458970/Nerium International added new ingredient, SIG-1273®, to the Optimera Formula of its Age-Defying Night and Day Creams. Engineered by Princeton University biochemist, Jeffry Stock, SIG-1273 is the result of 20 years of intensive biomedical skincare research, accordi
- Dr. Reddy's and its Subsidiary Promius Pharma File Three NDAshttps://practicaldermatology.com/news/dr-reddys-and-its-subsidiary-promius-pharma-announce-filing-of-three-ndas/2458971/Dr. Reddy's Laboratories and its subsidiary, Promius Pharma, LLC filed three 505(b)(2) New Drug Applications (NDAs) with the FDA. The three NDAs - DFD-01, DFD-09, and DFN-11, are in support of Dr. Reddy’s Proprietary Products group, focused on developing and commercializing therapies in